Abstract-CD9, a widely expressed membrane protein of the tetraspanin family, has been implicated in diverse functions, such as signal transduction, cell adhesion, and cell motility. We tested the effects of an anti-CD9 monoclonal antibody (ALMA.1) on the migration and proliferation of human vascular endothelial cells (ECs) during repair of an in vitro mechanical wound mimicking angiogenic processes. ALMA.1 induced dose-dependent inhibition of wound repair with a 35Ϯ1.5% decrease at 20 g/mL. Only cell migration was affected, because the rate of proliferation of ECs at the lesion margin was not modified and because the inhibition of repair was also observed for nonproliferating irradiated ECs. Monoclonal antibodies against CD63 tetraspanin (H5C6) and control mouse IgG (MOPC-21) were inactive. CD9, one of the most abundant proteins at the surface of ECs, colocalized with ␤ 1 or ␤ 3 integrins on EC membranes in double-labeling immunofluorescence experiments with ALMA.1 and an anti-␤ 1 (4B4) or anti-␤ 3 (SDF.3) monoclonal antibody. Moreover, ALMA.1 and 4B4 had additive inhibitory effects on lesion repair, whereas 4B4 alone also inhibited EC proliferation. In transmembrane Boyden-type assays, ALMA.1 induced dose-dependent inhibition of EC migration toward fibronectin and vitronectin with 45Ϯ6% and 31Ϯ10% inhibition, respectively, at 100 g/mL. 4B4 inhibited migration toward fibronectin at 10 g/mL but had no effect in the case of vitronectin. Adhesion of ECs to immobilized anti-CD9 monoclonal antibodies induced tyrosine-phosphorylated protein levels similar to those observed during interactions with ␤ 1 or ␤ 3 integrins. These results point to the involvement of CD9 in EC adhesion and migration during lesion repair and angiogenesis, probably through cooperation with integrins. As such, CD9 is a potential target to inhibit angiogenesis in metastatic and atherosclerotic processes. 
C
D9 is a widely expressed transmembrane protein of the tetraspanin superfamily (also known as TM4SF) with a broad tissue distribution and regulated expression depending on the embryonic or developmental stage. 1,2 CD9 is found in various tumor cells, 3, 4 in neural tissue, 5 and in the vasculature in endothelial cells (ECs), 6 smooth muscle cells, 7 and platelets. 8 Transfection experiments and the development of specific monoclonal antibodies (mAbs) have contributed to define possible functions for CD9. First, CD9 has been implicated in motility and tumor processes. 9, 10 Overexpression in adenocarcinoma cells suppresses the motility and metastatic potential, 10 CD9 expression in breast and pulmonary cancer is inversely related to the metastatic stage and to patient survival, 4 and anti-CD9 mAbs inhibit the motility of various leukemic cell lines 11 but enhance Schwann cell migration. 5 Second, CD9 has been found to participate in cell adhesion and aggregation. Anti-CD9 mAbs increase neutrophil adherence to endothelium 12 and adhesion of lymphocyte progenitors to bone marrow stromal fibroblasts 13 and induce the aggregation of strongly CD9-positive leukemic cell lines, 11 whereas immobilized anti-CD9 mAbs promote the adhesion of Schwann cells. 14 Finally, CD9 has been implicated in signal transduction. 15, 16 However, because of their short intracytoplasmic domains, it would seem unlikely that intracellular signaling can occur through TM4SF molecules alone. The wide diversity of functions attributed to tetraspanins is probably related to the association of these molecules with other protein complexes.
Coimmunoprecipitation and cocapping experiments have demonstrated that some tetraspanins facilitate the association of coreceptor molecules, such as CD4 and CD8 on T cells, and that some tetraspanins form tetraspanin complexes, which can in turn associate with coreceptors or integrins. Thus, CD9 forms complexes with CD81 or CD63, which associate with ␣ v ␤ 1 or ␣ 6 ␤ 1 integrins (reviewed in Reference 1). In platelets, where anti-CD9 antibodies trigger aggregation, CD9 is associated with the integrin ␣ IIb ␤ 3 . [17] [18] [19] Similarly, CD9 associates with ␤ 1 integrins in various leukemic cell lines and inhibits their transmembrane migration. 11 Another member of TM4SF, CD63, which has been identified on activated platelets 20 and is a component of Weibel-Palade bodies in ECs, 21 participates in adhesion processes and also forms specific complexes with some ␤ 1 integrins in human fibrosarcoma and erythroleukemia cell lines. 22 Several years ago, we developed a model of a mechanical wound in confluent ECs that allows the concomitant study of cell migration and proliferation during the repair process and mimics mechanisms encountered in angiogenesis. 23, 24 In view of the crucial role of angiogenesis in tumor progression and metastasis 25 and the relevance of integrins and their association with tetraspanins in these processes, 26, 27 we tested in the present study the effects of anti-tetraspanin antibodies on the migration and proliferation of human vascular ECs during lesion repair. We also examined the effects of these antibodies on transmembrane migration toward matrix proteins in a modified Boyden chamber assay. Finally, we investigated the possible colocalization of CD9 with ␤ 1 and ␤ 3 integrins in ECs.
Methods

Materials
Cell culture medium (medium 199 with Hanks' salts/RPMI 1640), HEPES, PBS with Dulbecco's formulation, trypsin-EDTA, L-glutamine, antibiotics (penicillin and streptomycin), and fungizone were from GIBCO. Tissue-culture Petri dishes (35-mm diameter) were from Corning Glass Works; 24-and 96-multiwell plates and cell-culture insert migration chambers, from Falcon, BectonDickinson Co; and Laboratory-Tek tissue-culture chamber slides, from Nunc, Inc. Pooled heat-inactivated human serum (HS), hepatitis B, and HIV-free and HS albumin (HSA) were from the Etablissement de Transfusion Sanguine de Strasbourg. Human fibronectin (FN) and vitronectin (VN) were purified from human plasma as previously described. 28, 29 Anti-CD9 mAbs (clone ALMA.1, IgG1, ; clone ALMA.3, IgG2a, ; and clone RPM.13, IgG1, ), anti-CD81 mAb (clone Z81.1, IgG1, ), and anti-␤ 3 mAb (clone SDF.3, IgG2a, ) were produced by a previously described procedure in mice immunized with washed human platelets. The hybridoma culture supernatants were screened for binding to recombinant GST-CD9 fusion protein by ELISA 30 and for binding to washed platelets by flow cytometry or immunoprecipitation of biotin-labeled platelet protein. 31 Hybridomas secreting anti-CD9 or anti-␤ 3 mAbs were subcloned twice. Anti-CD9 F(abЈ) 2 fragments were prepared as follows: Purified ALMA.1 IgG (3 mg) was digested overnight at 37°C on a rocking platform with 400 g pepsin (Boehringer-Mannheim) in 0.1 mol/L sodium acetate and 0.15 mol/L NaCl, pH 4.5. After adjusting the pH to 7 with 1 mol/L Tris, digestion was checked by SDS-PAGE analysis. The digest was dialyzed against 3 changes of PBS buffer, pH 7.2, and applied to a Superdex 200 HR 10/30 column (Pharmacia Biotechnology) equilibrated in the same buffer. The F(abЈ) 2 -containing fraction still contaminated with intact IgG was finally purified on an ionexchange Mono Q-HR column (Pharmacia) by applying a linear 0 to 300 mmol/L NaCl gradient in 50 mmol/L Tris buffer, pH 8. The anti-CD63 mAb (clone H5C6, IgG1, ) has been described elsewhere, 32,33 the anti-␤ 1 mAb (clone 4B4, IgG1) was from Coulter (Coultronics), and the mAb to the Fc␥ RII receptor (clone IV.3, IgG2b) (MOPC-21) has also been described previously. 34 Purified mouse IgG1 ( chain) control immunoglobulins, biotinylated antiphosphotyrosine mAbs (clone PT 66), and Arg-Gly-Asp-Ser (RGDS) peptide were purchased from Sigma Immuno Chemicals (Sigma-Aldrich Corp), and horseradish peroxidase-conjugated streptavidin was from Pierce Chemical Co (Pierce Europe, B.V.). Sheep anti-bromodeoxyuridine (anti-BrdU) polyclonal antibodies were from Fitzgerald. Purified mouse IgG2a ( chain) (MOPC-173) control immunoglobulins were obtained from Pharminogen, Becton Dickinson Co. Normal donkey serum, normal goat serum, affinitypurified peroxidase-conjugated donkey anti-sheep IgG (minimal cross-reactivity to human proteins), normal mouse serum, Cy2-and Cy3-affiniPure goat anti-mouse IgG (GAM; minimal cross-reactivity to human, bovine, and horse serum proteins) and FITC-labeled GAM were from Jackson Immunoresearch Laboratories. Mowiol 4 -88 was obtained from Calbiochem-Novabiochem Corp. When it was required, the mAbs were dialyzed against PBS and filter-sterilized. Irradiation of cells was performed in an irradiator for blood products (model IBL437 C, Commissariat à l'Energie Atomique) with a 137 Cs radiation source delivering 10 Gy/73 s under water. Electrophoresis supplies were obtained from Bio-Rad Laboratories, Immobilon-P transfer membranes were from Millipore Corp, the enhanced chemiluminescence detection kit was from Amersham, and cellulose polyacetate paper (Sepraphore III, No. 51003) was from Gelmann. All other chemicals were of analytical grade and were from Sigma or Merck.
Cell Culture
Human saphenous vein or mammary artery ECs were collected from vessel fragments obtained during coronary bypass surgery and cultured as previously described. 35, 36 After they were thawed, the cells were seeded on purified human FN in culture dishes and used from the second to the fifth passages. The culture medium was medium 199/RPMI 1640 (50/50) containing 10 mmol/L HEPES, 2 mmol/L L-glutamine, 100 U/mL penicillin, 100 g/mL streptomycin, 0.25 g/mL fungizone, and 30% pooled heat-inactivated HS. Experiments performed with ECs from saphenous veins or mammary arteries gave similar results.
Adhesion Assay
In a first set of experiments, cell adhesion was determined for longer times under the usual optimized culture conditions. Trypsinized ECs were preincubated with antibodies for 30 minutes at room temperature under constant gentle shaking and seeded at a concentration of 5000 cells per square centimeter in medium containing 5% HS on FN-or VN-coated (7.2 to 10 g per well) 96-multiwell plates. After 24 hours, nonadherent cells were eliminated by extensive rinsing with PBS. Adherent ECs were fixed at room temperature in 2% paraformaldehyde (PF) solution for 20 minutes, stained with MayGrünwald Giemsa stain, and counted with the use of an inverted microscope (Nikon Diaphot-TMD) at ϫ100 magnification. In further experiments, cell adhesion was measured for shorter times in the absence of serum. The concentration of adhesive protein was lowered to 0.5 g per well, nonsaturated sites were blocked with 5% HSA, HS was replaced by 1% HSA, and inhibitory substances or antibodies were added to the wells immediately before EC seeding. The duration of the assays was limited to 30 minutes, and at the end of this period, the multiwell plates were processed as described above.
Proliferation Assay
ECs were seeded at a concentration of 5000 cells per square centimeter on FN-coated 96-multiwell plates in medium containing 30% HS. On days 1 and 4 after seeding, the medium was removed and replaced with fresh medium containing 10% HS and antibodies. At day 7, adherent ECs were fixed in 2% PF solution, and EC proliferation was estimated by quantification of crystal violet staining of the cells 37 with a microplate reader (Molecular Devices).
Mechanical Injury of Confluent ECs and Lesion Repair
The procedure for establishment of a mechanical lesion of confluent ECs in vitro and analysis of lesion repair has been described in earlier publications. 38, 39 Briefly, a 6-mm-diameter endothelial monolayer was detached from the underlying extracellular matrix with a disk of polyacetate paper. This step constituted time zero of the experiment. At this time, serum concentration in the medium was reduced to 5%, and antibodies were added. Antibodies were further added over a concentration range of 0.1 to 50 g/mL during the repair process, and nonimmune mouse IgG was used for the control. After an 18-hour pulse with 10 mol/L BrdU, culture dishes were removed on day 2 and fixed in 2% PF solution as described above.
In some experiments, to hinder the capacity of ECs to proliferate, culture dishes were irradiated before lesion development with 10 Gy, a dose that inhibits [ 3 H]thymidine incorporation by 80% to 90%. 23 Proliferating ECs were visualized by BrdU incorporation into the nuclei 40 by use of sheep anti-BrdU and peroxidase-conjugated donkey anti-sheep antibodies. Replicating cells displayed black nuclei after 3,3Ј-diaminobenzidine staining, whereas nonreplicating cells had light purple nuclei after Giemsa dye counterstaining.
Cell Migration Assay
Transmembrane cell migration assays 41, 42 were performed in modified Boyden chambers by use of cell culture inserts composed of a porous 8-m (1x10 5 pores per square centimeter) polyethyleneterephthalate membrane with a diameter of 6.25 mm and a thickness of 11 m. Soluble adhesive proteins (5 g/mL in 600 L of serum-free culture medium) were placed in the lower compartment (24-multiwell plate) and incubated at 37°C for 30 minutes before cell addition. Nonspecific random migration was determined by using HSA (5 g/mL) instead of adhesive proteins. ECs (10 5 cells in 100 L), preincubated with antibodies for 20 minutes at room temperature under gentle shaking, were added to the upper cell culture insert, and cell migration was measured after 6 hours of incubation at 37°C. Nonmigrating cells were removed from the upper surface of the insert with a cotton swab, whereas those that had migrated to the lower face of the membrane were fixed with 0.1% crystal violet in 0.1 mol/L sodium borate, pH 9.0, containing 2% ethanol. EC counts were performed as described above at ϫ200 magnification.
Detection of Protein Tyrosine Phosphorylation
Protein tyrosine phosphorylation was explored in different situations: (1) in adherent confluent ECs, (2) in ECs incubated in suspension with antibodies before seeding, and (3) in ECs adherent to adsorbed antibodies or adhesive proteins for a short time (30 minutes). The corresponding assays were performed as follows: (1) Confluent ECs in 35-mm-diameter Petri dishes were incubated in medium containing 5% HS and exposed for various time periods (15 minutes to 48 hours) at 37°C to anti-CD9 mAbs (50 g/mL), in the presence or absence of the phosphatase inhibitor sodium orthovanadate (50 mol/L). (2) Confluent ECs were trypsinized and seeded (2ϫ10 5 cells per well) on FN (0.5 g per well)-coated 24-multiwell plates. Antibodies (ALMA.1, 4B4, and SDF.3) at 50 g/mL or 1% HSA (control) were preincubated with the cells for 30 minutes at room temperature or added just before seeding, and ECs were allowed to adhere for 30 minutes at 37°C. (3) Trypsinized ECs were seeded (2ϫ10 5 cells per well) on antibody-coated 24-multiwell plates. The wells were first incubated with GAM (10 g/mL) overnight at 4°C and blocked with 5% HSA for 1 hour at 37°C. After they were rinsed with PBS, the wells were incubated with the antibodies (MOPC-21, MOPC-173, ALMA.1, 4B4, and SDF.3) at 10 g/mL for 2 hours at 37°C, and ECs were then added and allowed to adhere for 30 minutes at 37°C. At the end of the adhesion period, ECs from duplicate wells were fixed and stained as described in Mechanical Injury of Confluent ECs and Lesion Repair.
On completion of the assays (1 to 3), the cells were rinsed with PBS and solubilized in 500 L lysis buffer (40 mmol/L Tris, pH 6.8, 10% ␤-mercaptoethanol, 2% SDS, 10% glycerol, and 0.2% bromophenol blue) containing 1 mmol/L sodium orthovanadate, 5 g/mL 4-amidinophenylmethanesulfonyl fluoride, 5 g/mL leupeptin, and 8 g/mL aprotinin. The lysates were stored at Ϫ20°C until gel electrophoresis. Nuclei were removed by microcentrifugation, and after SDS-PAGE separation on 7.5% gels, the proteins were electroblotted onto Immobilon-P transfer membranes. The blots were then incubated for 2 hours at room temperature with biotinylated anti-phosphotyrosine mAbs, incubated for a further 2 hours with horseradish peroxidase-conjugated streptavidin, and developed by use of an enhanced chemiluminescent detection kit according to the manufacturer's instructions.
FACS Analyses
ECs grown to 70% or 100% confluence were washed extensively with PBS. Adherent cells were removed by incubation in PBS containing 5 mmol/L EDTA at 4°C for 10 minutes, by scraping the cells, or by quick enzymatic detachment (2 minutes, 37°C) in trypsin-EDTA solution (0.05%/0.02%) followed by enzyme inactivation in medium containing 30% HS. All 3 procedures gave similar results in fluorescence-activated cell sorting (FACS) analyses. The washed cells were resuspended at 10 6 cells per milliliter in RPMI medium containing 5% normal goat serum and 0.1% sodium azide, and 10 5 cells were incubated with the primary antibody (10 g/mL) for 1 hour on ice. After they were washed with PBS, the cells were incubated with FITC-labeled GAM (10 g/mL) for 1 hour on ice and analyzed with a cell sorter (FACScalibur, Becton Dickinson). Gates were set for analysis of intact cells only.
Double-Labeling Immunofluorescence
ECs grown on chamber slides were washed in PBS, fixed in 2% PF solution at room temperature, and then permeabilized and blocked in PBS containing 0.1% saponin and 1% BSA at 4°C overnight. The slides were incubated with a first set of primary antibodies (ALMA.1, SDF.3, 4B4, H5C6, MOPC-173, and MOPC-21) at 10 g/mL in PBS containing 0.1% saponin, 3% BSA, and 1% normal goat serum (PBS-SBN) for 1 hour; they were then washed in PBS and incubated with Cy2-or Cy3-conjugated GAM in PBS-SBN for 1 hour. Free sites were blocked with 1% normal mouse serum in PBS. After they were washed, the cells were incubated with a second set of primary antibodies (ALMA.1, SDF.3, 4B4, H5C6, MOPC-173, and MOPC-21) at 10 g/mL for 1 hour in PBS-SBN, washed again, and incubated with Cy2-or Cy3-conjugated GAM in PBS-SBN for 1 hour. The slides were then rewashed, mounted in Mowiol 4 -88 solution with coverslips, and examined under a fluorescence microscope (Leica, DMLD). Single-or double-labeled isotype controls visualized with Cy2-or Cy3-conjugated GAM were negative. In addition, labeling of specific primary antibodies with either Cy2-or Cy3-conjugated GAM in the first or second position did not modify their labeling pattern (data not shown).
Image Analysis
The repair process was followed quantitatively by image analysis with Visiolab 1000 software (Biocom) as previously described. 24, 39 After measurement of the lesion area, cell density was calculated by counting the nuclei in 4 random 0.25-mm 2 calibrated fields at the leading edge of the lesion, in duplicate samples for each condition. This method is independent of cell shape and size. The proliferating cells, visualized by BrdU incorporation, were expressed as the percentage of the cell density in the corresponding field. To facilitate the comparison of identical conditions in separate experiments, results were expressed as the percentage of the control value set at 100%.
Statistical Analyses
The effects of the various antibodies on lesion repair and EC adhesion, migration, and proliferation were compared by ANOVA followed by the Newman-Keuls test with the use of the statistical software STAT-ITCF (ITCF).
Results
Expression of CD9, CD63, CD81, ␤ 1 , ␤ 3 , and Fc␥RII on ECs Surface expression of CD9, CD63, and CD81 tetraspanins, ␤ 1 and ␤ 3 integrins, and Fc␥RII on ECs was examined by flow cytometry (Figure 1) . The widely expressed tetraspanins CD9 and CD81 and ␤ 1 integrin were strongly expressed at the surface of freshly trypsinized ECs. CD63 and ␤ 3 integrin displayed levels of expression Ϸ10 times lower, whereas no surface expression of Fc␥RII (CD32) could be detected on ECs. Confluent and proliferating ECs exhibited comparable levels of expression of the different proteins tested (data not shown). In subsequent experiments, ALMA.1 was used as the anti-CD9 mAb.
Effects of Anti-CD9, -CD63, -␤ 1 , and -␤ 3 Antibodies on EC Lesion Repair
Anti-CD9 (ALMA.1) and anti-␤ 1 and anti-␤ 3 antibodies tested in the range 0.1 to 50 g/mL induced dose-dependent inhibition of lesion repair with decreases of 35Ϯ5%, 41Ϯ3%, and 27Ϯ2.5%, respectively, at 50 g/mL (PϽ0.05) ( Figure  2A ). The percentage of proliferating cells at the lesion margin (see Methods) was not affected by anti-CD9 or anti-␤ 3 , suggesting that these antibodies did not act by inhibiting cell proliferation, whereas anti-␤ 1 reduced the percentage of proliferating cells by 28Ϯ3% at 20 g/mL (PϽ0.05). Anti-CD63 had no effect on lesion repair (Figure 2A ). Identical results were obtained when anti-CD9 F(ab)Ј 2 fragments were used instead of intact IgG (data not shown) or anti-CD9 from the clone ALMA.3, whereas antibodies from the clone RPM.13 against rat CD9 were inefficient. Low concentrations of anti-CD9 (1 g/mL) and anti-␤ 1 (1 g/mL) antibodies, each of which when added separately induced moderate but significant inhibition, had additive inhibitory effects on lesion repair, although the rate of cell proliferation was identical to the control rate ( Figure 2B) . To confirm the effect of the anti-CD9 antibody on cell migration, EC proliferation was blocked with a 10-Gy dose of radiation before establishing the lesion. As expected, anti-CD9 inhibited the lesion repair of irradiated ECs to the same extent (28%) as that of nonirradiated ECs (data not shown).
Effect of Anti-CD9 Antibodies on EC Proliferation
Sparsely seeded ECs were allowed to proliferate on FN in the presence of antibodies (0.1 to 50 g/mL) for 7 days. Compared with control values, neither anti-CD63, anti-␤ 3 , nor control IgG significantly affected EC proliferation at any of the concentrations tested, whereas anti-␤ 1 antibodies induced dose-dependent inhibition, reaching a plateau value of 28Ϯ11% (PϽ0.05) at 10 g/mL (Figure 3) . In contrast, anti-CD9 induced a significant increase in EC proliferation, with a mean of 40Ϯ4% at 20 g/mL.
Effect of Anti-CD9 Antibodies on EC Adhesion
Adhesion to FN-or VN-coated culture dishes under cell culture conditions was not modified in ECs preincubated with anti-CD9 antibodies (1 to 50 g/mL) for 30 minutes compared with ECs adhering in the absence of antibodies or after incubation with control IgG. Anti-␤ 1 was likewise inactive under these conditions (data not shown). When adhesion assays were performed for shorter incubation times in the absence of serum, anti-CD9 did not inhibit cell adhesion to either FN or VN but enhanced it by 19Ϯ3% (PϽ0.05, Figure  4 ). The controls, RGDS peptide (1 to 5 mmol/L), and EDTA (1 to 2 mmol/L) induced dose-dependent inhibition of EC adhesion to both FN and VN. In the same conditions, the anti-␤ 1 antibody 4B4 inhibited EC adhesion to FN slightly but significantly by 21Ϯ6% and 21Ϯ11% (PϽ0.05) at 10 and 20 g/mL, respectively, thus confirming the blocking capacity of this antibody, 43 which did not, however, inhibit adhesion to VN (Figure 4 ).
Anti-CD9 Antibodies Inhibit EC Transmembrane Migration Toward FN or VN
In Boyden chamber experiments, dose-dependent inhibition of migration of the cells toward FN or VN was induced in ECs incubated with anti-CD9 antibodies (ALMA.1) at 0.01 to 100 g/mL compared with ECs migrating in the absence of antibodies ( Figure 5) , with maximal effects of 45Ϯ6% for FN and 31Ϯ10% for VN (PϽ0.05). Anti-CD9 from the clone ALMA.3 was inefficient in transmembrane experiments. Anti-␤ 1 antibodies tested in the same concentration range induced 44Ϯ7% inhibition of EC migration toward FN at 10 g/mL (PϽ0.05). In contrast, higher concentrations of anti-␤ 1 no longer inhibited cell migration toward FN, whereas the same antibody had only little effect on migration toward VN at any concentration. Anti-CD63 antibodies (100 g/mL) did not affect EC migration toward FN or VN, and nonspecific migration determined with the use of HSA represented Ͻ1%. 
Effects of Anti-CD9, -␤ 1 , and -␤ 3 Antibodies on Tyrosine Phosphorylation During Adhesion of ECs
Adherent ECs display high levels of phosphorylated proteins that persist throughout cell growth and in resting confluent cultures. 44 Thus, when tyrosine-phosphorylated proteins were analyzed during lesion repair over a period of 48 hours in the presence of sodium orthovanadate to prevent degradation by phosphatases, the phosphorylation pattern was unchanged in the presence of anti-CD9 antibodies (50 g/mL; data not shown). Detachment of ECs led to a sharp decrease in the tyrosine phosphorylation of proteins within 30 minutes (Figure 6a) . When ECs were seeded in FN-coated wells, the level of tyrosine phosphorylation in cells adhering for 30 minutes increased significantly. In an identical number of adherent cells, there was no difference between ECs adhering in the presence of anti-CD9, anti-␤ 1 , or anti-␤ 3 antibodies added 30 minutes before seeding (Figure 6b ). Furthermore, identical phosphorylation patterns were observed in ECs incubated with the same antibodies for 30 minutes in suspension (data not shown).
The ability of these antibodies to capture ECs was tested after adsorption of the antibodies and of control IgG on tissue-culture-grade polystyrene. ECs did not adhere to all these substrates with the same efficiency. Adhesion was significantly diminished on mouse IgG, GAM, and HSA (IgGϾGAMϾHSA) but was equivalent on anti-CD9 (ALMA.1), anti-␤ 1 (4B4), anti-␤ 3 (SDF.3), FN, and VN (data not shown). However, equal numbers of ECs adhering to immobilized anti-CD9, anti-␤ 1 , or anti-␤ 3 antibodies or to control IgG showed similar patterns of tyrosine phosphorylation (Figure 6c ).
CD9 Colocalizes With ␤ 1 and ␤ 3 in ECs
Double-labeling immunofluorescence of ECs with anti-CD9 and anti-␤ 1 showed common labeling of structures at the cell surface and some intracellular structures (Figure 7) , suggesting the colocalization of CD9 with ␤ 1 integrins not only at the cell surface (especially at cell-cell junctions) but also inside the cell, presumably with the ␤ 1 integrin precursor. 45 ␤ 3 integrins similarly displayed colocalization with CD9. Identical experiments with anti-CD9 and anti-CD63 antibodies demonstrated that CD63 was essentially concentrated within intracellular granular structures clearly distinct from the mainly surface membrane locations of CD9.
Discussion
In the present study, we demonstrate that the tetraspanin CD9 participates in EC lesion repair in vitro, possibly by interact- 
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ing with ␤ 1 and ␤ 3 integrins. Anti-CD9 antibodies inhibited cell migration and had additive effects in the presence of an anti-␤ 1 antibody. In addition, CD9 and ␤ 1 were shown in double-immunolabeling experiments to localize to common structures at the surface of ECs. When cells were released from a confluent state, anti-CD9 antibodies inhibited only cell migration during lesion repair, whereas anti-␤ 1 antibodies affected both migration and proliferation. The effects of anti-CD9 were not mediated through Fc receptors because results could be reproduced by using F(abЈ) 2 fragments. Finally, anti-CD9 antibodies inhibited EC migration toward FN and VN in transmembrane Boyden-type migration assays. Angiogenesis, the sprouting of new capillaries from the preexisting vascular bed, occurs in many physiological and pathological situations and proceeds through a sequence of events typically involving proteolytic degradation of the basement membrane, migration and proliferation of ECs, lumen formation, and reconstitution of a new basal membrane. 46, 47 Triggering of angiogenesis requires stimulation signals, whereas temporal regulation of activators and inhibitors adds to the complexity of the process. 48 The relevance of angiogenesis in tumor processes is now well established. 49 Recent research has focused on the regulation of cellular signals by extracellular matrix proteins in the context of cell adhesion and angiogenesis, and integrins have been shown to play a major role in these mechanisms. 26,50 -52 In the study of cancer, the importance of the association of tetraspanins with integrins is now emerging, 27 although no involvement of these complexes in angiogenesis has yet been reported in vivo. Recently, 2 studies have reported modulation by tetraspanins (CD151 and CD81) of in vitro collagen gel invasion and capillary formation, possibly through interactions with integrins or other associated molecules. 53, 54 Among the nearly 20 identified members of the tetraspanin family, several are expressed in ECs, with some at high levels (CD151/PETA3, 54 CD9, CD63, and CD81) ( Figure 1 ) and others only at low levels (CD53, A15/TALLA, and CO-029) (data not shown).
Lesion repair and angiogenesis are processes that share a number of common events, including EC migration and proliferation. Using a previously developed model of a mechanical wound in confluent ECs that preserves the neosynthesized extracellular matrix, 55 we demonstrated in the present study that an anti-CD9 mAb (ALMA.1) inhibits lesion closure. Because this effect could be reproduced with F(abЈ) 2 fragments, it would appear to be independent of Fc receptors. This is in contrast to the platelet aggregation induced by several anti-CD9 mAbs, which is mediated by the Fc␥RII receptor, 16, 56, 57 even though platelet activation specific to immobilized F(abЈ) 2 fragments of CD9 has also been described. 57 Lesion repair results from 2 complementary processes: cell migration and proliferation. Although cell adhesion precedes migration, both processes use common adhesion receptors in the form of cytoskeletal proteins and extracellular matrices, which are differently regulated. 58 Anti-CD9 mAbs affected EC migration but not proliferation during lesion repair, in view of the fact that the proliferation rate at the leading edge of the lesion remained identical to that of controls. Furthermore, when irradiated ECs in which proliferation was severely hindered were used, 23 anti-CD9 mAbs still inhibited lesion closure. EC adhesion was not modified by an anti-CD9 mAb (ALMA.1) under conditions in which RGDS peptide and EDTA induced significant inhibition. Moreover, this antibody did not inhibit the proliferation of sparsely seeded ECs on FN but increased it, which would further reinforce the involvement of CD9 in EC migration during lesion repair. Additional data in support of an effect on migration were obtained from transmembrane Boyden-type assays, in which an anti-CD9 mAb inhibited EC migration toward FN and VN with a potency similar to that observed in lesion repair. Specificity to CD9 was demonstrated by the lack of effect of another tetraspanin mAb, anti-CD63. However, all anti-CD9 mAbs tested did not display the same activity. Among our mAbs to CD9 (ALMA.1, ALMA.3, and RPM.13), ALMA.1 was the most potent, ALMA.3 inhibited EC migration during lesion repair to the same extent as did ALMA.1 but was inefficient in transmembrane assays, and RPM.13 did not inhibit lesion closure. These differences in activity are difficult to explain because competition experiments indicate the epitopes of these antibodies to be similar if not identical (data not shown). Nevertheless, the same antibodies also display variable agonist efficiency in platelet aggregation with a similar order of potency (ALMA.1ՆALMA.3ϾRPM.13) (data not shown).
The intracellular domains of tetraspanins and, hence, of CD9 would appear to be too short to induce signal transduction on their own and do not contain domains known to participate in signal transduction. Consequently, many functions assigned to these molecules must result from their association with other molecules present at the cell surface and especially with integrins. 1 Integrins play a fundamental role in angiogenesis 26 through their ability to interact with the extracellular matrix proteins on which ECs adhere and migrate. 51, 52 These interactions of integrins with the extracellular matrix mediate coupling to several signaling pathways and the recruitment of signaling molecules, such as focal adhesion kinase (FAK), Ras, and Rho. 59 In the present study, we demonstrate the inhibitory effects of anti-␤ 1 and anti-␤ 3 mAbs on lesion repair and confirm the relevance of integrins to this process. Although anti-␤ 1 mAbs slightly (Ϸ20%) inhibited the adhesion of sparsely seeded ECs under sensitive adhesion conditions, this property of ␤ 1 would seem insufficient to account for its inhibitory effect observed on wound closure because lesion repair occurred in postconfluent adhering EC cultures. Our data further suggest that CD9, but not CD63, could cooperate with ␤ 1 integrins in mediating EC migration for the following reasons: (1) low concentrations of anti-CD9 and anti-␤ 1 mAbs had additive effects on lesion repair, (2) both antibodies inhibited transmembrane migration toward FN, and (3) ␤ 1 and CD9 colocalized to common structures on the surface of ECs. The common localization of CD9 and ␤ 1 integrins at the cell junctions of human umbilical vein ECs was recently reported and, likewise, their coimmunoprecipitation. 54 However, whereas the anti-CD9 mAb (ALMA.1) inhibited EC migration toward both FN and VN, the anti-␤ 1 mAb inhibited only EC migration toward FN. This indicates that CD9 could associate at least with the ␤ 1 integrin receptors for FN and is in agreement with other reports showing that the adhesive properties of CD9 involve interactions with this protein. 9, 60, 61 Finally, ALMA.1 also inhibited EC migration toward von Willebrand factor (data not shown). Because the VN and von Willebrand factor receptors belong to the ␤ 3 integrins, these results suggest an association of CD9 with ␤ 3 integrins in ECs that is similar to that occurring in platelets [17] [18] [19] ; this was confirmed in double-immunolabeling assays in which CD9 and ␤ 3 colocalized to some common structures of ECs. Immunoprecipitation experiments that used various cellular models like platelets, leukemic cells, keratinocytes, and Schwann cells have shown a physical proximity between CD9 and the ␤ 1 and ␤ 3 integrins. CD9 associates with very late antigen (VLA)-3, VLA-4, VLA-5, and VLA-6, among which VLA-3 and VLA-5 bind to FN, 9, 11, 14, 17, 54 but the mechanism and type of interaction remain unknown. Our results support the most recent model of a web or lattice at the cell surface, formed by tetraspanins associated with integrins, where these tetraspanins would act as "adaptor proteins" or "molecular facilitators." 1 CD9 could modulate the affinity of integrins for their ligands by direct interaction or through a yet-unidentified common stimulatory pathway.
To date, neither the type nor the mechanism of signal transduction through CD9 is known, no natural ligand has yet been described, and antibodies are the only tools available. Depending on the cell system, mAbs to CD9 appear to facilitate 5 or inhibit (Reference 11 and the present study) cell motility. Similarly, (over)expression of CD9 suppressed the motility of tumor cell lines, 10 whereas its transfection into CD9-negative human B-cell lines enhanced their migratory properties. 9 The effects observed in the presence of mAbs could be due to phosphorylation or dephosphorylation processes. In platelets, anti-CD9 mAbs induce an increase in the tyrosine phosphorylation of several proteins, some of which (1) anti-CD9 (mAb ALMA.1), which was revealed by Cy3 labeling, and then anti-␤ 1 (mAb 4B4), which was revealed by Cy2 labeling; (2) anti-CD9, which was revealed by Cy2 labeling, and then anti-␤ 3 (mAb SDF.3), which was revealed by Cy3 labeling; or (3) anti-CD9, which was revealed by Cy2 labeling, and then anti-CD63 (mAb H5C6), which was revealed by Cy3 labeling, as described in Methods. Photomicrographs are representative of 8 separate experiments. Original magnification ϫ400.
belong to the Src family and others of which have been identified as p72 syk and p125
FAK
. 15, 62 Expression of CD9 in a human B-cell line increases the tyrosine phosphorylation of 69-and 130-kDa bands in cells adhering to FN, 9 whereas in Schwann cells, anti-CD9 mAbs enhance the tyrosine phosphorylation of 8-to 220-kDa proteins. 5 In the experimental conditions under which we observed inhibition of lesion repair, ALMA.1 did not modify the tyrosine phosphorylation profile of ECs over a period of 48 hours, even in the presence of a phosphatase inhibitor, to reveal low phosphorylation levels, nor did clustering of CD9 modify this profile (data not shown). Tyrosine-phosphorylated proteins were strongly downregulated in ECs after trypsinization and resuspension. This confirms the findings of Defilippi et al, 44 who demonstrated a rapid downregulation of tyrosine-phosphorylated proteins in ECs detached from their substratum. Tyrosine phosphorylation was then increased to higher levels within 30 minutes under limiting adhesion conditions on FN and VN, and these levels were not affected by anti-CD9, anti-␤ 1 , or anti-␤ 3 antibodies. In addition, identical phosphorylation patterns were observed in ECs adhering to FN, VN, or immobilized anti-CD9 or antiintegrin antibodies. These results demonstrate the following: (1) The adhesion of ECs induces high levels of protein phosphorylation (which persist in increasing) and stationary confluent cultures. 44 (2) Immobilization of the receptor through matrix proteins like VN, FN, collagen I, collagen IV, and laminin 44 or through other substrates, such as antibodies that allow the adhesion of ECs, induces a similar phosphorylation response. Furthermore, identical responses were obtained when these substrate molecules bound to ECs in suspension (data not shown). This is in agreement with the observation that integrin clustering, per se, in nonadherent ECs triggers p125 FAK tyrosine phosphorylation. 44 ( 3) The ability of ECs to adhere to immobilized anti-CD9 mAbs and thus promote tyrosine phosphorylation comparable to that induced by interactions with ␤ 1 or ␤ 3 integrins (Reference 44 and the present study) demonstrates that CD9 participates actively in EC adhesion, either by itself or through interactions with integrins or other as-yet-unidentified proteins. As in the case of cell migration, these observations reinforce the hypothesis of the existence of cooperative mechanisms between CD9 and integrins in ECs. However, the signal(s) induced by the anti-CD9 mAb ALMA.1 during EC lesion repair still remains unknown.
In conclusion, our results point to the important role of CD9 in EC migration during lesion repair and possibly during angiogenesis. CD9 is thought to cooperate with integrins to modulate EC migration on FN and VN, and in view of the major role of ECs in angiogenesis and the relevance of this process to cancer, CD9 could represent a potential target to inhibit angiogenesis during metastatic processes.
